Cite
Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction
MLA
Clotilde Roy, et al. “Fibroblast Growth Factor 23: A Biomarker of Fibrosis and Prognosis in Heart Failure with Preserved Ejection Fraction.” ESC Heart Failure, vol. 7, no. 5, Oct. 2020, pp. 2494–507. EBSCOhost, https://doi.org/10.1002/ehf2.12816.
APA
Clotilde Roy, Sibille Lejeune, Alisson Slimani, Christophe deMeester, Sylvie A. Ahn AS, Michel F. Rousseau, Amzulescu Mihaela, Audrey Ginion, Benjamin Ferracin, Agnès Pasquet, David Vancraeynest, Christophe Beauloye, Jean‐Louis Vanoverschelde, Sandrine Horman, Damien Gruson, Bernhard L. Gerber, & Anne‐Catherine Pouleur. (2020). Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Failure, 7(5), 2494–2507. https://doi.org/10.1002/ehf2.12816
Chicago
Clotilde Roy, Sibille Lejeune, Alisson Slimani, Christophe deMeester, Sylvie A. Ahn AS, Michel F. Rousseau, Amzulescu Mihaela, et al. 2020. “Fibroblast Growth Factor 23: A Biomarker of Fibrosis and Prognosis in Heart Failure with Preserved Ejection Fraction.” ESC Heart Failure 7 (5): 2494–2507. doi:10.1002/ehf2.12816.